287 related articles for article (PubMed ID: 35278245)
1. Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.
Duckworth EJ; Murugesan N; Li L; Rushbrooke LJ; Lee DK; De Donatis GM; Maetzel A; Yea CM; Hampton SL; Feener EP
Clin Exp Allergy; 2022 Sep; 52(9):1059-1070. PubMed ID: 35278245
[TBL] [Abstract][Full Text] [Related]
2. Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II.
Joseph K; Tholanikunnel BG; Bygum A; Ghebrehiwet B; Kaplan AP
J Allergy Clin Immunol; 2013 Aug; 132(2):470-5. PubMed ID: 23672780
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
Kaplan AP; Joseph K
Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213
[TBL] [Abstract][Full Text] [Related]
4. Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.
Kaplan AP; Joseph K
Clin Rev Allergy Immunol; 2016 Oct; 51(2):207-15. PubMed ID: 27273087
[TBL] [Abstract][Full Text] [Related]
5. KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results.
Maetzel A; Smith MD; Duckworth EJ; Hampton SL; De Donatis GM; Murugesan N; Rushbrooke LJ; Li L; Francombe D; Feener EP; Yea CM
J Allergy Clin Immunol; 2022 Jun; 149(6):2034-2042. PubMed ID: 35086692
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12.
Bhattacharjee G; Revenko AS; Crosby JR; May C; Gao D; Zhao C; Monia BP; MacLeod AR
Nucleic Acid Ther; 2013 Jun; 23(3):175-87. PubMed ID: 23582057
[TBL] [Abstract][Full Text] [Related]
7. Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema.
Davie RL; Edwards HJ; Evans DM; Hodgson ST; Stocks MJ; Smith AJ; Rushbrooke LJ; Pethen SJ; Roe MB; Clark DE; McEwan PA; Hampton SL
J Med Chem; 2022 Oct; 65(20):13629-13644. PubMed ID: 36251573
[TBL] [Abstract][Full Text] [Related]
8. Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies.
Farkas H; Balla Z
Expert Opin Investig Drugs; 2024 Mar; 33(3):191-200. PubMed ID: 38366937
[TBL] [Abstract][Full Text] [Related]
9. Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade.
Busse P; Kaplan A
J Allergy Clin Immunol Pract; 2022 Mar; 10(3):716-722. PubMed ID: 34838707
[TBL] [Abstract][Full Text] [Related]
10. The bradykinin-forming cascade and its role in hereditary angioedema.
Kaplan AP; Joseph K
Ann Allergy Asthma Immunol; 2010 Mar; 104(3):193-204. PubMed ID: 20377108
[TBL] [Abstract][Full Text] [Related]
11. A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain.
Ivanov I; Matafonov A; Sun MF; Mohammed BM; Cheng Q; Dickeson SK; Kundu S; Verhamme IM; Gruber A; McCrae K; Gailani D
Blood; 2019 Mar; 133(10):1152-1163. PubMed ID: 30591525
[TBL] [Abstract][Full Text] [Related]
12. High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency.
Suffritti C; Zanichelli A; Maggioni L; Bonanni E; Cugno M; Cicardi M
Clin Exp Allergy; 2014 Dec; 44(12):1503-14. PubMed ID: 24552232
[TBL] [Abstract][Full Text] [Related]
13. Biochemistry, molecular genetics, and clinical aspects of hereditary angioedema with and without C1 inhibitor deficiency.
Miyata T; Horiuchi T
Allergol Int; 2023 Jul; 72(3):375-384. PubMed ID: 37169642
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Hereditary Angioedema.
Caballero T
J Investig Allergol Clin Immunol; 2021 Feb; 31(1):1-16. PubMed ID: 33602658
[TBL] [Abstract][Full Text] [Related]
15. Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema.
Joseph K; Tholanikunnel BG; Kaplan AP
J Allergy Clin Immunol; 2017 Jul; 140(1):170-176. PubMed ID: 27826093
[TBL] [Abstract][Full Text] [Related]
16. Bradykinin-mediated diseases.
Kaplan AP
Chem Immunol Allergy; 2014; 100():140-7. PubMed ID: 24925394
[TBL] [Abstract][Full Text] [Related]
17. Hereditary angioedema: Pathophysiology (HAE type I, HAE type II, and HAE nC1-INH).
Wedner HJ
Allergy Asthma Proc; 2020 Nov; 41(Suppl 1):S14-S17. PubMed ID: 33109319
[TBL] [Abstract][Full Text] [Related]
18. Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor.
Joseph K; Tholanikunnel BG; Kaplan AP
J Allergy Clin Immunol; 2009 Jul; 124(1):143-9. PubMed ID: 19342086
[TBL] [Abstract][Full Text] [Related]
19. Hereditary angioedema in childhood: an approach to management.
Ebo DG; Verweij MM; De Knop KJ; Hagendorens MM; Bridts CH; De Clerck LS; Stevens WJ
Paediatr Drugs; 2010 Aug; 12(4):257-68. PubMed ID: 20593909
[TBL] [Abstract][Full Text] [Related]
20. Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation.
Clermont AC; Murugesan N; Edwards HJ; Lee DK; Bayliss NP; Duckworth EJ; Pethen SJ; Hampton SL; Gailani D; Feener EP
Front Pharmacol; 2023; 14():1287487. PubMed ID: 38178859
[No Abstract] [Full Text] [Related]
[Next] [New Search]
